N
Google TrendNOVIG (2000+) — Novig Sign Up Bonus: ROTOWIRE Gets $50 in Trade Credits
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:novig2000+boise state vs fresno state500+sounders500+pedro pascal200+medicare2000+blade200+kings vs golden knights1000+white sox vs cleveland guardians match player stats1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Sustained MRD Negativity" (30 stories)

Top Headline Story

IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
Lead StoryTargeted Oncologygeneral
Sep 26

IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxONDVHYTl2dlh1NlF1TVVlSS0xOXNJRk82N0RNa2VJck14ZVhPdlpJRjJkRWQxeERaanZzSTdKLXlSaHZ5eFlKOWMzZU8wNGViQzlZc1FnNEhfY29jeDJ5bU9fMnplYy1PWkp2SlZPcGVYRTJmNXFNY3RPWlBLSFFtYTBuYmd0aEdGOGJvS0Z4MGw5bUk?oc=5" target="_blank">IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+23m ago

novig

Novig Sign Up Bonus: ROTOWIRE Gets $50 in Trade Credits

Filter stories
500+23m ago

boise state vs fresno state

Boise State gets big health boost, but injury concerns remain vs. Fresno State

Filter stories
500+23m ago

sounders

NEvsSEA Starting XI: Dejan Joveljić and Yeimar return to starting lineup, Sebastian Gomez gets the nod

Filter stories
200+23m ago

pedro pascal

Pedro Pascal in ‘Behemoth!’: The Oscar-Worthy Role That He (and Latinos) Have Been Waiting For

Filter stories

Search Results for "Sustained MRD Negativity"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
OncLivetech

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPbGtlSUNtNnFHem81enRPNVQ1RGlkM2RsNU1mc3NhaGZfSEJjSXRQRG9ib3F0MmxwMkh3NkhWMy1JSXd3bDhDb2FzOEN3OGpQTFBzNU5DRktfMHY0YkhVQXY2UXJXUjhPWmU5MEpucHpZV1dNV3FsbzRFV3FJQlprbEk3MHFBNVA2T0VJMXptcVMxQWNzTUZyNndVOE0?oc=5" target="_blank">Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Sustained MRD Negativity Predicts Long-Term Outcomes in Multiple Myeloma
HMP Global Learning Networktech

Sustained MRD Negativity Predicts Long-Term Outcomes in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPNVVudG5pZVhMZ2RFTnI4Sy1VRzVZN0MwZkJBdWZoUUN0aG5CVkl0aUdrUTFRSUpsZ05JUWJ2ZHc5WmszcHpIaVR5U2h6SFpFQVVBdzJHYTUtMUJYRE1Za0Jvb25hYVNhMl9ZSHNNX0djZklhS0xiQjJyOFR4VVVvczFTRWh5NkVfLUtfNUx6SzhucllQemNwckFDdjBQV2dOM2VUazJtOHpiZVd5cEhxZlFnNjA1WkloYVpGRUFJUUwzbndP?oc=5" target="_blank">Sustained MRD Negativity Predicts Long-Term Outcomes in Multiple Myeloma</a>  <font color="#6f6f6f">HMP Global Learning Network</font>

Read Full StoryMore like this
Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM
CancerNetworkgeneral

Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRWJzNTMycU10RXRtanpacWdIWlhGMTFWSGZNU2ZOQmdfb1NsbU9jYnFHZU9GMEVES1BHdkFJUENzdjRUX1hfaXhaR2ZlTERUS1hyajBPc29mWmliejRPQzdDUjAxN0hiVmZxT1NqbUFDNlNlS1RsVG1sZlRBZ09zMlBCb1RabVNrNlFQYzEteEM0eWlfSUJLYVFwVFRjRGIySjJqMWE2aE0?oc=5" target="_blank">Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Isatuximab Boosts MRD Negativity in Multiple Myeloma
Medscapegeneral

Isatuximab Boosts MRD Negativity in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOSXlFdXdGMG1vZnpkVDFXaGc4TDJxTU8ySWduUkZDclFXa0VOVWJaZ2pJeE9PYmtMUFBnbDc0QThOa25HYjhhMnJrSkcxQktzeWstUF9lVkFFVm4xbDJ6X3Mwejk4ZnRaUDd1enUzOWZhSTN2OWNVUk5BZW9iRm9uS3ktQ29aT3J4elBBeGlFNVhfWVQ5d0dVdUNLeHpiTXVr?oc=5" target="_blank">Isatuximab Boosts MRD Negativity in Multiple Myeloma</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
Naturetech

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBvdGFONXNEZjFXNTJ6dnhSeWJzU3RTVU1fRzl1Z21yaTZ5dndNNmJVLXRubUs5ZUJhLUpGek9TcWxhSTlvemc3aV8yUmtQNmdBV3J1cFhaNzZUZU04NmZZ?oc=5" target="_blank">Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
CEPHEUS Data Show Deeper MRD Response With D-VRd in Newly Diagnosed Myeloma
Targeted Oncologygeneral

CEPHEUS Data Show Deeper MRD Response With D-VRd in Newly Diagnosed Myeloma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNX3ZLMW1HNlNyNklTVWo1eFplNXJRNjAyV1JBVHg5NTk3SzJxOXdvRWNWZm96eTQzbjhSVGdRclZjRVV2eWk5NWswR0tZeGRoVkVYRzlPai1OZjVaM1U2eHMyTjNRMDh6eTVFZGk0XzZ0N2gzdFNTMXBhQlNMYlNKVHk4QXBIdjQ0NEJlNmRUdnJORlQtSHIwQ1FBZ0xoRVBpVDN3dzl2UmlSNG5t?oc=5" target="_blank">CEPHEUS Data Show Deeper MRD Response With D-VRd in Newly Diagnosed Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma
Fierce Biotechgeneral

FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPVVYzWWtJMDNGRllyTmV6WGhFQUlOX1JfVEdqV2RUdnpVYl9nVU1YRUlmSFc2UGp1ZTBsekZpaWs2TXEzY0VRQ3hPbFRhdi05WUNDcTA0WHd1eUtmRkJScnFlbDAzQzZqc1lDT1UtODBIN2FCd1pyUzNrdG1pRmdYQ3hQUEQ2QXVIMzdpWVZpeG0xeXAwRGJPVHQwNmFNV1cxbFdTbEc3ekpVN0lEWlhQcWRmcEswSGJaZms4NFM5c0Y2dw?oc=5" target="_blank">FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
MRD End Point Brings “Positive Change” to Multiple Myeloma Research
CancerNetworkgeneral

MRD End Point Brings “Positive Change” to Multiple Myeloma Research

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNU1NMdDZUSzhHOTc3b0gzQjRMekR0V1FKUHFMVDJwN0o3WUh0LWxma20zZHZidkcxQUIwQ3ZTU1VzZVVIV1lmMlM4WHcwVTVieHhKbGZhM2duZlVyUkUyMkV5MHlCdlZpQ09vU1I4X3BxNmxLRE1ISnZKUEZHMUlLX3dlVlNYNlZHRDhJZjNkeEp2MUxTZW9TbzIzMU1HX0sycmc?oc=5" target="_blank">MRD End Point Brings “Positive Change” to Multiple Myeloma Research</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)
OncLivetech

Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)

<a href="https://news.google.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?oc=5" target="_blank">Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Can Isa-VRd Sustain MM Minimal Residual Disease Negativity?
Medscapetech

Can Isa-VRd Sustain MM Minimal Residual Disease Negativity?

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPY19INU9XTHFjVk9NdHRtVzYwal91WVVkZHJyWG5BcFpoaXZ3ajBMT3J1T28xdXpOX0ZEWWxSWW1uYTAzak10VWhqS25BSFZPazk1NE9JclBjdVNxb0c2dDJUcEpwdC1JX1FKX1YwSkY1QVhaLVEtdjd5dVZDclFQRVRhSGU4WEw4ODk3NWN1UzIwYWcyM2Y4R3REZGozbko2R1RjLTlB?oc=5" target="_blank">Can Isa-VRd Sustain MM Minimal Residual Disease Negativity?</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma
Targeted Oncologytech

Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQTjhGTDNEY2FDNnd4aV8zeVFPOVktOHpaMGNMWDZZS2d0Vk1CclVSOVNDR090aFJNRVhrSnRpb19XdHRfd084UFcxMG00dFptODJWZk9xYU5HU0dWZmlQaVVidkZsT2dHZnZpMjV4dDU4Wk5CVVNGUTk4eVJCbU1FZUQ5ak9pU3lrMDR1eXdVVmFrdXhjZnFyc1hvMDhpUHMxby1NLXR6MTVsaXRIZXc?oc=5" target="_blank">Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
OncLivetech

CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPX21zRldISHptSi13RVB5QWQ2V2VOMmFEY1hZQzFIXzhwNk5HTXhFWi1uT2tHSHZSR2pTOHlRTXFJa3FJdlpGZmVwal9Qa1pRSmhEcGFmZVA1c2c3dFZ4Z0U2blFhdjZTQ1FyRGZtZnR3elZvaTRzSGdpdHFONTNJMC0xOVBVODZVUXNIdzdoaXVXSTlWRDdxY2U0d18xYjQtU2d3NElXaXkta291U3VNUmFCNDBzRmpzcFROVDNGQlZfQVZpbEUzWUpRT0lvTWJhSkNpemppQzA?oc=5" target="_blank">CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma
CancerNetworkgeneral

Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQdXdROUdnRjNGcmJNc25hMW50blNDRW05TU5xOXhLMVR2SUJvaEpHNjBPMnpUbklBVGROTTNXU1VpcC02aGJ0WUhqc1laZjVpSG9ZUWJibG1uY2FKUTI2WElIak1VVW5tSF84RjI4UDk1STBPd1VtRTNlekpFSnVLT3lLMTRURUU1NWFrQzlZalEzMG52QUZMdlJCZ3htb2RwN3R3NGJ5emRZSGhwMzVHamVWNUVTUQ?oc=5" target="_blank">Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Dr Lonial on Using MRD Negativity to Guide Maintenance Discontinuation in Myeloma
Targeted Oncologytech

Dr Lonial on Using MRD Negativity to Guide Maintenance Discontinuation in Myeloma

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQOWdfSUVCWEhaX1JiRXZfaTgtaHlGcTJtMlhIVUM0RXBIU05VMkdwdkJoS3BOb1g4bGJWUW9VSUFsU3ZpU2VBRjZmVV9fUkVkTVE2eGp0UE9tRlYybi1mVWxIcHBCT0lDOUk4RlRicGZROW9LT1pscldZd3VSMy1OUGJXSUdXQkJXU2ZzTFAxdnZoLXFPOG9EeUtBOE1TUUsyaVR2aEpZY01pTUJuWVdhc25MWlQ?oc=5" target="_blank">Dr Lonial on Using MRD Negativity to Guide Maintenance Discontinuation in Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial
CancerNetworkgeneral

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOX0EzdXJMY0pITHNCS28xTHhkM1hVblJnS3dIMFJoakNIVmJucGlPQ1g5MVplUnJaWDNfZDRfdC1VbXdlazZKS05MZDdnODFWemVIOEVzeVZxeDl1bFlLcWduQkZxUHZzX053b3dkRnktWVNiRm1ySXdXUDRqVHZSbDM5SzYybHhETGxRYmlKOE4wa0NEQlBxQkxYTUxEQkl6ZWZvNWdKdHFWYUhwM3E4R0ZLd3hRVm1FUHh4YkhvMTRfYTljN3RZbA?oc=5" target="_blank">Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma
OncLivegeneral

Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQbVlTNUl1TlQxMm1pY0NrRGt4cG4yN3NYNVVNZXJkdUZ3Z011ZFF3X18xNVdZQzA1SmUxVjM5dFlJYUpoZ1lOR2tHX3A3V01MMEF2MmhnUE14MkZrSWduenNDeFIwLWxlUlc3aDY4QW9HVHlfTVFDTVB0OENGZXZYSk1pYnd1NVIwTDhLc21fMldYMWMzNzZwdHhZalgtenN4cmxBNUpNMjhQUmR1?oc=5" target="_blank">Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma
Targeted Oncologygeneral

Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQck5rOTg2eEVfWmZ0UnFIcVJCT0tOMXBrWUdnMjJmSEdaRUdtTnR2ay1FRUczb20tWDNJcmRlZkxETjVuVFNVY01ZOEZqZDdUVGgyckEtMHVIcl9YUXh1Ry10algyXy1mTWs2X3NRSnppOEV5dzJkLTREOWRUcTUwSlE5OUNTR1F5YkhrRUZRcEp4R255UU1LT3hiNVZWLVNkVlE?oc=5" target="_blank">Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Belantamab Mafodotin Combo Sustains MRD Negativity/PFS in Multiple Myeloma
CancerNetworktech

Belantamab Mafodotin Combo Sustains MRD Negativity/PFS in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNY1BqeVY2SmVmZFlFYnZlUGZHazktWVRIa2VlZnh0UEVRUjd0Z1hoMFNYODhlRU1FZENCdGlGMlBOTUFMT0h4ZGN6bFNYWnotcXFwTWdXLXdYZ3dBNTBnV21mNGMtSU9URDlGc3JHNjI5OGVaWW4tV1BSVjlTTm5La3N0VVRJTFpseHN4QmNmNDh0bnRSYUh2M0lqWmJBbVFGaHNjUEVGNk56eWplSGc?oc=5" target="_blank">Belantamab Mafodotin Combo Sustains MRD Negativity/PFS in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma
Targeted Oncologytech

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNdVo2WGhIMlBsV3BuTHdYaVNhWW1UcTFiRjJ2Rmt2RWsxbzY4QlZwNExaUU93ZURCX1FnN2dTcVVmeHhfM0lZME9UOXZlRE8zc1R0WEszc1dyTUkzR2p3Z0NHcGw3aHJSQ212QmllNmVUdVdrcVFZMnQzcFFRUmhnMkQ1dDhtT0dtbU9NSEVRcHNVZGZrcUN2MnVER3g5aGRhcWZORlhLSUJZUFoxMnVEckVR?oc=5" target="_blank">Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma
OncLivegeneral

Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNRTRXWlRFR2ZSZXZCMlMyR1VBMHJfaW9fZ3kwQVZXZGhBZ0t3Y0p3S2twS0ZZdTZ5RktyckxrdVRVaDJ0ak5zdVdBR0FTOXZNdlBuNXBWSVUzbkdIdzRrazdvakNBUXpDNEx6XzUtdnJqMGsyY28tQ0pwd2JKSnEwUWFmSFp1bGR5OU5FT0FneEVYTDRpZEMzOHdTbmhhVjN2NFZDbjlQV0Rrc1cxQUo4?oc=5" target="_blank">Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Long-Term BENEFIT Data Affirm Isa-VRd as Standard of Care in Transplant-Ineligible NDMM
Pharmacy Timesgeneral

Long-Term BENEFIT Data Affirm Isa-VRd as Standard of Care in Transplant-Ineligible NDMM

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOTWlOS01laGhvM0U0Q3RTdDBQdmdoNGp0dGFWWEFhS1hVUUtGdUxiRUJ0TzlRam1uY0I2R1ZCTkp6T0stOUhHUWd3eFFOeU5zX1VmeWRnY1hCdkpfcG1oN0s2VllBTHdWamt6dU9MS2NhYTlfM2lFd3dWM29Bc0RDSVJzUjRJeTMwNFIwOHBKN2JYQ2JHeDdFSUlabmZVTzQ0T3B6Y2ZnNzFJcll6ZHhJeFkxQXpXMXhQZkE4QnIzMA?oc=5" target="_blank">Long-Term BENEFIT Data Affirm Isa-VRd as Standard of Care in Transplant-Ineligible NDMM</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025
OncLivegeneral

Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNSnU5dW5Nc25IVmpBTnBaWmx2Ym8xS3FUMkUtOEp2SkVLTDhacHNadUNhdEFhMHBYelMwUHRUQlFuS2ZCUFZ0M1AxWTJQSmVidDJjWmZGMUdoa0hYZmpzSG41bEZJVVFqeGlmdnRGMjJidURaZlJmM0d6UVlJX3JPVmgwTjFrd21vZXJaYkVQRE5iWVFFYXc?oc=5" target="_blank">Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients
Oncology News Centraltech

Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPN1pUZk9hX1lrcmNadGY1WVdHQUM2eTlSZWxXcnhpaGQyVWtsdXBObUxaMndnU0p2ZnhtWkVjVHRFLTRtMjY2T0t5MTM2WkVJUVp2S3FKZzV2SjZqZ09jWmJVV0RiTmI3SVMzUmlHdFVKaXhpS2lPRUpnSUxMYUlraVNaZnEwS0N2cUtOR1FvUzBUWDNEaGUzZVpMNHl0elJUQ3FxYUVQYkpscVNxdDVFcHpRQ3U5Mkd4VXQ5b2NXVEVwYVJva2hYTW16UnNFcHRLVGc?oc=5" target="_blank">Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy
Targeted Oncologytech

Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPZ00weFVmR00zUktRT1RnUVF1aHlXdVdPN1Jrd2lqUE1heWxHYzNCRG1QNUctMm5XcEtfVlY5c0R3T3J1WnBsQmVnX3FzOW5VSkN3TEkwSVZLT0RwMVVWUkhBcjVud2VBaG1PdmdMVUFjTXVZTVI2RXNRTXBjNFRVZ0hHemNKeFFaeDRhcHhqM0dzYWxzT3JtYldtbUpzaWFx?oc=5" target="_blank">Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma
OncLivetech

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOVDFvVlBST1pjWHl2Y0pOQVgxZURGbFBGd3J1NjQ3OS1CWFRXOU9sNE5DTkF5Vk1RNVpHVk05Wm54NVdjTmlGZHlNQmE5b2p2dnY5WVp2Q2NqYmk1cC01NHRIVnA4dFQzWXVnMHMzaFptQlpRTnM5bkZHUi12MmlNb2NuZnVib0tReWc5YXhBZkZDUWNaV1VGb25zZWd1T1haSW1tLXRyc0RlSldVdlZPSFJEdnhPUUVoRW82eg?oc=5" target="_blank">MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma
The ASCO Posttech

Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOSXFCbFRKdXFlU2VQNjczc2tyczZHcTNyVUpNR0d5TkdrNWY3T3EyYVV3ejlzRFdhanVNRVB6THVlVnRjaDNYMnlDSFZEaUhZUkdjUE9HcjZBRkdMSDB0MlU5Y2FSYmd0Mk1pTEVPZWdsLW53NkFBMVpzQU85bWN3aDNzUUxOaElRRmczOERNbVVQZzIzN3pvd0EwaG5lbDhYUHlkY3lxcFlGWTBpUDk4WE0tdnZUUGRwMXpnQ3NFOTJ6c2QyS1lN?oc=5" target="_blank">Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Dara-VRd Leads to Sustained MRD Negativity in Newly Diagnosed Myeloma
Targeted Oncologytech

Dara-VRd Leads to Sustained MRD Negativity in Newly Diagnosed Myeloma

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxObEhkeWZWTWp5M2NEY0g2aldIYkVjQ2Nnd0pHYmZGY19YcWNKZGVPbWEwMlJmQ1c0bjlzalJPRUo5NU1SR1VNelVtejBrUUhsazJZY2JBNjZRdW9EYmFzeDFfM1RPdWRfMXZNMDhEdE90NXQ1SXJwU1ItYm9nNFNQRW0yQk5vTWhaOUJUWll5YUtzXzRmcndiTXNGcS1iMG9qdmVyOQ?oc=5" target="_blank">Dara-VRd Leads to Sustained MRD Negativity in Newly Diagnosed Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma
OncLivegeneral

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPejdfcG5xcmJOVDd6RHZFcVpUVG5iaURCY0JaUDhTRWY4bmdjS3BFRHB0ZV85a3o3anRMbmxYVmwtcjhBR1hxWW1YMFEya3BqNUpsUnA3T3RXWkNvWks1TGdiZ2NHRndRWW5ZcXo3dkFTV1gtOTRoMmZuTDVWMmVaZ2h5MkUwaGZEc2Y2RUxjRlZXeGdxSE5ic0xqTGRMZkJKMTBlQVBMN3U0TGJpZXBYeQ?oc=5" target="_blank">Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM
CancerNetworktech

Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxORmNyU1poRHhCQzduZVZlRkRZUkNUa29ueVFLd2U4ZTNaUjNXdy1kRmV0Nmg5UkJpNW40Szd3RnVFdk1vZkFzN0JDTXZvSHJ0SFpuVXk2QVVTRWlkX0p5UDM2by1LWHhvS3BHZE51WjBseHRkMXdJRGZoWG1NTzR3QWhWYkZjRllWYVBmRHBaSll0NTZzYjhvalFMemh4ZG1FamJYcg?oc=5" target="_blank">Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
"Sustained MRD Negativity" — Live Google News Trends & Headlines